Prospects for Enhancing Efficacy of Radioimmunotherapy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-04-25

AUTHORS

Clément Bailly , Caroline Bodet-Milin , François Guérard , Caroline Rousseau , Michel Chérel , Françoise Kraeber-Bodéré , Jean-François Chatal

ABSTRACT

Radioimmunotherapy has been in use for more than 20 years and has progressed significantly since its efficacy has first been demonstrated in hematology. Yet it still has limitations that prevent its large-scale clinical use. This chapter reviews recent developments to overcome these limitations including new antibody specificities, pretargeting methods, fractionated injections, and the use of alpha emitters. Immuno-PET is also likely to assist in selecting patients for radioimmunotherapy, optimizing injected activities, and noninvasively monitoring therapy efficacy. More... »

PAGES

139-153

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_10

DOI

http://dx.doi.org/10.1007/978-3-319-78238-6_10

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103656152


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "CHU, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.463837.d", 
          "name": [
            "CHU, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailly", 
        "givenName": "Cl\u00e9ment", 
        "id": "sg:person.0665453076.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CHU, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.463837.d", 
          "name": [
            "CHU, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bodet-Milin", 
        "givenName": "Caroline", 
        "id": "sg:person.01212260416.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.463837.d", 
          "name": [
            "CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gu\u00e9rard", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.0673143706.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673143706.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.463837.d", 
          "name": [
            "ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousseau", 
        "givenName": "Caroline", 
        "id": "sg:person.01240530667.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.463837.d", 
          "name": [
            "ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ch\u00e9rel", 
        "givenName": "Michel", 
        "id": "sg:person.01224071104.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CHU, ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.463837.d", 
          "name": [
            "CHU, ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraeber-Bod\u00e9r\u00e9", 
        "givenName": "Fran\u00e7oise", 
        "id": "sg:person.0653324404.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, Nantes-Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GIP Arronax, Nantes-Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatal", 
        "givenName": "Jean-Fran\u00e7ois", 
        "id": "sg:person.0623457423.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-04-25", 
    "datePublishedReg": "2018-04-25", 
    "description": "Radioimmunotherapy has been in use for more than 20\u00a0years and has progressed significantly since its efficacy has first been demonstrated in hematology. Yet it still has limitations that prevent its large-scale clinical use. This chapter reviews recent developments to overcome these limitations including new antibody specificities, pretargeting methods, fractionated injections, and the use of alpha emitters. Immuno-PET is also likely to assist in selecting patients for radioimmunotherapy, optimizing injected activities, and noninvasively monitoring therapy efficacy.", 
    "editor": [
      {
        "familyName": "Hosono", 
        "givenName": "Makoto", 
        "type": "Person"
      }, 
      {
        "familyName": "Chatal", 
        "givenName": "Jean-Fran\u00e7ois", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-78238-6_10", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-78237-9", 
        "978-3-319-78238-6"
      ], 
      "name": "Resistance to Ibritumomab in Lymphoma", 
      "type": "Book"
    }, 
    "keywords": [
      "efficacy of radioimmunotherapy", 
      "new antibody specificities", 
      "large-scale clinical use", 
      "immuno-PET", 
      "injected activity", 
      "therapy efficacy", 
      "clinical use", 
      "antibody specificity", 
      "radioimmunotherapy", 
      "efficacy", 
      "patients", 
      "hematology", 
      "injection", 
      "alpha emitters", 
      "use", 
      "years", 
      "specificity", 
      "activity", 
      "limitations", 
      "development", 
      "recent developments", 
      "method", 
      "chapter", 
      "prospects", 
      "emitters"
    ], 
    "name": "Prospects for Enhancing Efficacy of Radioimmunotherapy", 
    "pagination": "139-153", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103656152"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-78238-6_10"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-78238-6_10", 
      "https://app.dimensions.ai/details/publication/pub.1103656152"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_259.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-78238-6_10"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_10'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_10'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_10'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_10'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      22 PREDICATES      48 URIs      41 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-78238-6_10 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N167d6dbd08b941599da3ec5f3a2792c3
4 schema:datePublished 2018-04-25
5 schema:datePublishedReg 2018-04-25
6 schema:description Radioimmunotherapy has been in use for more than 20 years and has progressed significantly since its efficacy has first been demonstrated in hematology. Yet it still has limitations that prevent its large-scale clinical use. This chapter reviews recent developments to overcome these limitations including new antibody specificities, pretargeting methods, fractionated injections, and the use of alpha emitters. Immuno-PET is also likely to assist in selecting patients for radioimmunotherapy, optimizing injected activities, and noninvasively monitoring therapy efficacy.
7 schema:editor N3170fcbe1b504549a76c2f0def76e529
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nc3776e543629470f90d6f8bd084beb38
11 schema:keywords activity
12 alpha emitters
13 antibody specificity
14 chapter
15 clinical use
16 development
17 efficacy
18 efficacy of radioimmunotherapy
19 emitters
20 hematology
21 immuno-PET
22 injected activity
23 injection
24 large-scale clinical use
25 limitations
26 method
27 new antibody specificities
28 patients
29 prospects
30 radioimmunotherapy
31 recent developments
32 specificity
33 therapy efficacy
34 use
35 years
36 schema:name Prospects for Enhancing Efficacy of Radioimmunotherapy
37 schema:pagination 139-153
38 schema:productId Nbd0e41a2c75646658680a23e738d50a6
39 Nf4060d6c98fb484ab3a1c7f0bc99ce81
40 schema:publisher N9f6e415ec97741ca96cf8c0b31599d6d
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103656152
42 https://doi.org/10.1007/978-3-319-78238-6_10
43 schema:sdDatePublished 2022-12-01T06:49
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher N8ee8950bd8924b709cc1750c7cfedf6a
46 schema:url https://doi.org/10.1007/978-3-319-78238-6_10
47 sgo:license sg:explorer/license/
48 sgo:sdDataset chapters
49 rdf:type schema:Chapter
50 N1387d6d27204439ba319b71918eb8f29 schema:familyName Chatal
51 schema:givenName Jean-François
52 rdf:type schema:Person
53 N14cf91a658ba401e822d7068a944c717 rdf:first sg:person.0673143706.40
54 rdf:rest N7065bd151bd84672b1e6f0e2306286e0
55 N167d6dbd08b941599da3ec5f3a2792c3 rdf:first sg:person.0665453076.40
56 rdf:rest N382e8536c0bc4048984cbccf06a6ddd1
57 N2295209defd448b89e7bfd40075a5dc7 rdf:first sg:person.0623457423.87
58 rdf:rest rdf:nil
59 N3170fcbe1b504549a76c2f0def76e529 rdf:first Ne391595ce580458ab75bd64ad8d705f4
60 rdf:rest N6f89d68241ef42ba823e1c625f8c28bb
61 N382e8536c0bc4048984cbccf06a6ddd1 rdf:first sg:person.01212260416.00
62 rdf:rest N14cf91a658ba401e822d7068a944c717
63 N6f89d68241ef42ba823e1c625f8c28bb rdf:first N1387d6d27204439ba319b71918eb8f29
64 rdf:rest rdf:nil
65 N7065bd151bd84672b1e6f0e2306286e0 rdf:first sg:person.01240530667.47
66 rdf:rest Ne0f880bd158b4316976d0b6d87e1ddd1
67 N8ee8950bd8924b709cc1750c7cfedf6a schema:name Springer Nature - SN SciGraph project
68 rdf:type schema:Organization
69 N9f6e415ec97741ca96cf8c0b31599d6d schema:name Springer Nature
70 rdf:type schema:Organisation
71 Nbd0e41a2c75646658680a23e738d50a6 schema:name dimensions_id
72 schema:value pub.1103656152
73 rdf:type schema:PropertyValue
74 Nc3776e543629470f90d6f8bd084beb38 schema:isbn 978-3-319-78237-9
75 978-3-319-78238-6
76 schema:name Resistance to Ibritumomab in Lymphoma
77 rdf:type schema:Book
78 Ne0f880bd158b4316976d0b6d87e1ddd1 rdf:first sg:person.01224071104.01
79 rdf:rest Nf376680661564585a3dad268e29ad615
80 Ne391595ce580458ab75bd64ad8d705f4 schema:familyName Hosono
81 schema:givenName Makoto
82 rdf:type schema:Person
83 Nf376680661564585a3dad268e29ad615 rdf:first sg:person.0653324404.03
84 rdf:rest N2295209defd448b89e7bfd40075a5dc7
85 Nf4060d6c98fb484ab3a1c7f0bc99ce81 schema:name doi
86 schema:value 10.1007/978-3-319-78238-6_10
87 rdf:type schema:PropertyValue
88 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
89 schema:name Medical and Health Sciences
90 rdf:type schema:DefinedTerm
91 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
92 schema:name Clinical Sciences
93 rdf:type schema:DefinedTerm
94 sg:person.01212260416.00 schema:affiliation grid-institutes:grid.463837.d
95 schema:familyName Bodet-Milin
96 schema:givenName Caroline
97 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00
98 rdf:type schema:Person
99 sg:person.01224071104.01 schema:affiliation grid-institutes:grid.463837.d
100 schema:familyName Chérel
101 schema:givenName Michel
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01
103 rdf:type schema:Person
104 sg:person.01240530667.47 schema:affiliation grid-institutes:grid.463837.d
105 schema:familyName Rousseau
106 schema:givenName Caroline
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
108 rdf:type schema:Person
109 sg:person.0623457423.87 schema:affiliation grid-institutes:None
110 schema:familyName Chatal
111 schema:givenName Jean-François
112 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87
113 rdf:type schema:Person
114 sg:person.0653324404.03 schema:affiliation grid-institutes:grid.463837.d
115 schema:familyName Kraeber-Bodéré
116 schema:givenName Françoise
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
118 rdf:type schema:Person
119 sg:person.0665453076.40 schema:affiliation grid-institutes:grid.463837.d
120 schema:familyName Bailly
121 schema:givenName Clément
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40
123 rdf:type schema:Person
124 sg:person.0673143706.40 schema:affiliation grid-institutes:grid.463837.d
125 schema:familyName Guérard
126 schema:givenName François
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673143706.40
128 rdf:type schema:Person
129 grid-institutes:None schema:alternateName GIP Arronax, Nantes-Saint-Herblain, France
130 schema:name GIP Arronax, Nantes-Saint-Herblain, France
131 rdf:type schema:Organization
132 grid-institutes:grid.463837.d schema:alternateName CHU, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
133 CHU, ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
134 CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
135 ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
136 schema:name CHU, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
137 CHU, ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
138 CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
139 ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes, Nantes, France
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...